References
1. Ahuja CS, Wilson JR, Nori S, et al. Traumatic spinal cord injury. Nat
Rev Dis Primers. 2017;3: 17018. Published 2017 Apr 27.
doi:10.1038/nrdp.2017.18
2. Jain NB, Ayers GD, Peterson EN, et al. Traumatic spinal cord injury
in the United States, 1993-2012. JAMA. 2015;313(22):2236-2243.
doi:10.1001/jama.2015.6250
3. Hubscher CH, Herrity AN, Williams CS, et al. Improvements in bladder,
bowel and sexual outcomes following task-specific locomotor training in
human spinal cord injury. PLoS One. 2018;13(1):e0190998. Published 2018
Jan 31. doi:10.1371/journal.pone.0190998
4. Quel de Oliveira C, Refshauge K, Middleton J, de Jong L, Davis GM.
Effects of Activity-Based Therapy Interventions on Mobility,
Independence, and Quality of Life for People with Spinal Cord Injuries:
A Systematic Review and Meta-Analysis. J Neurotrauma.
2017;34(9):1726-1743. doi:10.1089/neu.2016.4558
5. Baldassin V, Shimizu HE, Fachin-Martins E. Computer assistive
technology and associations with quality of life for individuals with
spinal cord injury: a systematic review. Qual Life Res.
2018;27(3):597-607. doi:10.1007/s11136-018-1804-9
6. Elmelund M, Klarskov N, Bagi P, Oturai PS, Biering-Sørensen F. Renal
deterioration after spinal cord injury is associated with length of
detrusor contractions during cystometry-A study with a median of 41
years follow-up. Neurourol Urodyn. 2017;36(6):1607-1615.
doi:10.1002/nau.23163
7. Hamid R, Averbeck MA, Chiang H, et al. Epidemiology and
pathophysiology of neurogenic bladder after spinal cord injury. World J
Urol. 2018;36(10):1517-1527. doi:10.1007/s00345-018-2301-z
8. Myers JB, Lenherr SM, Stoffel JT, et al. Patient Reported Bladder
Related Symptoms and Quality of Life after Spinal Cord Injury with
Different Bladder Management Strategies. J Urol. 2019;202(3):574-584.
doi:10.1097/JU.0000000000000270
9. Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic
drugs for adult neurogenic detrusor overactivity: a systematic review
and meta-analysis. Eur Urol. 2012;62(5):816-830.
doi:10.1016/j.eururo.2012.02.036
10. Krhut J, Borovička V, Bílková K, et al. Efficacy and safety of
mirabegron for the treatment of neurogenic detrusor
overactivity-Prospective, randomized, double-blind, placebo-controlled
study. Neurourol Urodyn. 2018;37(7):2226-2233. doi:10.1002/nau.23566
11. Blok B, Castro-Diaz D, Del Popolo G, et al., EAU Guidelines on
Neuro-urology. EAU Guidelines. Edn. presented at the EAU Annual Congress
Amsterdam 2020. ISBN 978-94-92671-07-3.
12. Andersson KE. Potential Future Pharmacological Treatment of Bladder
Dysfunction. Basic Clin Pharmacol Toxicol. 2016;119 Suppl 3:75-85.
doi:10.1111/bcpt.12577
13. Andersson KE. Pharmacotherapy of the overactive bladder. Discov Med.
2009;8(42):118-124.
14. Carbone A, Palleschi G, Conte A, et al. Gabapentin treatment of
neurogenic overactive bladder. Clin Neuropharmacol. 2006;29(4):206-214.
doi:10.1097/01.WNF.0000228174.08885.AB
15. Kim YT, Kwon DD, Kim J, Kim DK, Lee JY, Chancellor MB. Gabapentin
for overactive bladder and nocturia after anticholinergic failure. Int
Braz J Urol. 2004;30(4):275-278. doi:10.1590/s1677-55382004000400002
16. Ansari MS, Bharti A, Kumar R, Ranjan P, Srivastava A, Kapoor R.
Gabapentin: a novel drug as add-on therapy in cases of refractory
overactive bladder in children. J Pediatr Urol. 2013;9(1):17-22.
doi:10.1016/j.jpurol.2011.10.022
17. Dash V, Bawa M, Mahajan JK, Kanojia RP, Samujh R, Rao KL. Role of
gabapentin and anticholinergics in management of neurogenic bladder
after repair of spina bifida - a randomized controlled study. J Pediatr
Surg. 2016;51(12):2025-2029. doi:10.1016/j.jpedsurg.2016.09.030
18. Chua ME, See MC 4th, Esmeňa EB, Balingit JC, Morales ML Jr. Efficacy
and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult
Overactive Bladder Treatment. Low Urin Tract Symptoms.
2018;10(2):135-142. doi:10.1111/luts.12152
19. Ferro S, Cecconi L, Bonavita J, Pagliacci MC, Biggeri A,
Franceschini M. Incidence of traumatic spinal cord injury in Italy
during 2013-2014: a population-based study. Spinal Cord.
2017;55(12):1103-1107. doi:10.1038/sc.2017.88
20. Joseph C, Andersson N, Bjelak S, et al. Incidence, aetiology and
injury characteristics of traumatic spinal cord injury in Stockholm,
Sweden: A prospective, population-based update. J Rehabil Med.
2017;49(5):431-436. doi:10.2340/16501977-2224
21. Joseph C, Andersson N, Bjelak S, et al. Incidence, aetiology and
injury characteristics of traumatic spinal cord injury in Stockholm,
Sweden: A prospective, population-based update. J Rehabil Med.
2017;49(5):431-436. doi:10.2340/16501977-2224
22. Chen Y, He Y, DeVivo MJ. Changing Demographics and Injury Profile of
New Traumatic Spinal Cord Injuries in the United States, 1972-2014. Arch
Phys Med Rehabil. 2016;97(10):1610-1619. doi:10.1016/j.apmr.2016.03.017
23. Kim KT, Chang HK, Kim CH, et al. Basic neurourology. J Exerc
Rehabil. 2019;15(6):747-750. Published 2019 Dec 31.
doi:10.12965/jer.1938744.372
24. Chung YG, Seth A, Doyle C, et al. Inosine Improves Neurogenic
Detrusor Overactivity following Spinal Cord Injury. PLoS One.
2015;10(11):e0141492. Published 2015 Nov 3.
doi:10.1371/journal.pone.0141492
25. Oliveira R, Coelho A, Franquinho F, Sousa MM, Cruz F, D Cruz C.
Effects of early intravesical administration of resiniferatoxin to
spinal cord-injured rats in neurogenic detrusor overactivity. Neurourol
Urodyn. 2019;38(6):1540-1550. doi:10.1002/nau.24032
26. Wada N, Kadekawa K, Majima T, et al. Urodynamic effects of
intravenous and intrathecal administration of E-series prostaglandin 1
receptor antagonist on detrusor overactivity in rats with spinal cord
injury. Neurourol Urodyn. 2018;37(1):132-137. doi:10.1002/nau.23319
27. Miyazato M, Sasatomi K, Hiragata S, et al. GABA receptor activation
in the lumbosacral spinal cord decreases detrusor overactivity in spinal
cord injured rats. J Urol. 2008;179(3):1178-1183.
doi:10.1016/j.juro.2007.10.030
28. Andrade EL, Forner S, Bento AF, et al. TRPA1 receptor modulation
attenuates bladder overactivity induced by spinal cord injury. Am J
Physiol Renal Physiol. 2011;300(5):F1223-F1234.
doi:10.1152/ajprenal.00535.2010
29. Santos-Silva A, Charrua A, Cruz CD, Gharat L, Avelino A, Cruz F. Rat
detrusor overactivity induced by chronic spinalization can be abolished
by a transient receptor potential vanilloid 1 (TRPV1) antagonist. Auton
Neurosci. 2012;166(1-2):35-38. doi:10.1016/j.autneu.2011.09.005
30. Ogawa T, Sasatomi K, Hiragata S, et al. Therapeutic effects of
endothelin-A receptor antagonist on bladder overactivity in rats with
chronic spinal cord injury. Urology. 2008;71(2):341-345.
doi:10.1016/j.urology.2007.10.025
31. Khera M, Boone TB, Salas N, Jett MF, Somogyi GT. The role of the
prostacyclin receptor antagonist RO3244019 in treating neurogenic
detrusor overactivity after spinal cord injury in rats. BJU Int.
2007;99(2):442-446. doi:10.1111/j.1464-410X.2007.06615.x
32. Sasatomi K, Hiragata S, Miyazato M, Chancellor MB, Morris SM Jr,
Yoshimura N. Nitric oxide-mediated suppression of detrusor overactivity
by arginase inhibitor in rats with chronic spinal cord injury. Urology.
2008;72(3):696-700. doi:10.1016/j.urology.2007.12.002
33. Ozkürkçügil C, Kömür O, Ozkan L. Effect of memantine on overactive
detrusor in rats with spinal cord injury. Kaohsiung J Med Sci.
2010;26(5):251-255. doi:10.1016/S1607-551X(10)70036-X
34. Krhut J, Borovička V, Bílková K, et al. Efficacy and safety of
mirabegron for the treatment of neurogenic detrusor
overactivity-Prospective, randomized, double-blind, placebo-controlled
study. Neurourol Urodyn. 2018;37(7):2226-2233. doi:10.1002/nau.23566
35. Maniscalco GT, Aponte R, Bruzzese D, et al. THC/CBD oromucosal spray
in patients with multiple sclerosis overactive bladder: a pilot
prospective study. Neurol Sci. 2018;39(1):97-102.
doi:10.1007/s10072-017-3148-6
36. Schröder A, Albrecht U, Schnitker J, Reitz A, Stein R. Efficacy,
safety, and tolerability of intravesically administered 0.1% oxybutynin
hydrochloride solution in adult patients with neurogenic bladder: A
randomized, prospective, controlled multi-center trial. Neurourol
Urodyn. 2016;35(5):582-588. doi:10.1002/nau.22755
37. Watanabe M, Yamanishi T, Honda M, Sakakibara R, Uchiyama T, Yoshida
K. Efficacy of extended-release tolterodine for the treatment of
neurogenic detrusor overactivity and/or low-compliance bladder. Int J
Urol. 2010;17(11):931-936. doi:10.1111/j.1442-2042.2010.02635.x
38. Schulte-Baukloh H, Mürtz G, Heine G, et al. Urodynamic effects of
propiverine in children and adolescents with neurogenic bladder: results
of a prospective long-term study. J Pediatr Urol. 2012;8(4):386-392.
doi:10.1016/j.jpurol.2011.07.014
39. Amarenco G, Sutory M, Zachoval R, et al. Solifenacin is effective
and well tolerated in patients with neurogenic detrusor overactivity:
Results from the double-blind, randomized, active- and
placebo-controlled SONIC urodynamic study. Neurourol Urodyn.
2017;36(2):414-421. doi:10.1002/nau.22945
40. Weckx F, Tutolo M, De Ridder D, Van der Aa F. The role of botulinum
toxin A in treating neurogenic bladder. Transl Androl Urol.
2016;5(1):63-71. doi:10.3978/j.issn.2223-4683.2016.01.10
41. Davari M, Amani B, Amani B, Khanijahani A, Akbarzadeh A, Shabestan
R. Pregabalin and gabapentin in neuropathic pain management after spinal
cord injury: a systematic review and meta-analysis. Korean J Pain.
2020;33(1):3-12. doi:10.3344/kjp.2020.33.1.3
42. Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of
gabapentin and pregabalin abuse, misuse, dependence, or overdose: An
analysis of the Food And Drug Administration Adverse Events Reporting
System (FAERS). Res Social Adm Pharm. 2019;15(8):953-958.
doi:10.1016/j.sapharm.2018.06.018
Table 1. Clinical data of the cohort 1.